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Abstract 
Objectives: The most common bleeding disorders in women are described as Asrigdara in Ayurveda, 
characterized by Pradirana (excessive excretion) of Raja (menstrual blood). It can be correlated to ‘Dysfunctional 
Uterine Bleeding’ in modern medicine. In modern medicine hormonal therapy, anti-prostaglandins & anti-
fibrinolytic agents have not proven their definitive efficacy in spite of high costs; their side effects have led to 
hormonal imbalances. Methods: In order to overcome the above abnormalities, we conducted a clinical trial for 90 
days on 30 patients of age group 18-45 yrs. We administered Shunthi Churna (2 gms.) and Lodhra Churna (3gms) 
mixed with Sharkara (5 gms.) i.e. total (10gms) thrice daily with cold water, after food. Two observations were 
taken, 1st after 45 days of treatment and the 2nd one after completion of treatment on various parameters like 
amount and duration of blood loss, inter-menstrual period, passage of clots and pain during menstruation. Results: 
Based on the parameters studied, we observed 60% of patients improved moderately, 36.7% showed mild-
improvement, 3.3% showed marked-improvement in different symptoms. The results are highly significant on 
most parameters. Conclusion: Drug formulation Shunthi Churna and Lodhra Churna with Sharkara, proved to be 
effective in treating most of the symptoms of Asrigdara..  
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Introduction 
Dysfunctional uterine bleeding (DUB) is defined 
as a state of excessive abnormal uterine bleeding 
without any clinically detectable organic pelvic 
pathology. The abnormality may be in frequency, 
duration or amount or combination of all (1). Normal 
menstrual cycle varies from 21-35 days with the 
bleeding phase of 4-6 days with an average loss of 35-
45 ml of blood (2).  Abnormal menstrual cycle is 
defined as any deviation from the aforesaid. The 
disease Asrigdara explained in Ayurveda may be 
closely co-related with the condition Dysfunctional 
uterine bleeding of contemporary medical science. 
According to Acharya Charaka, if the menstrual 
cycle turns to be abnormal due to Pradirana (excessive 
secretion) of Raja, it is termed as Pradara (3). 
According to Acharya Sushruta, excessive and 
prolonged bleeding during menstruation or even in inter
-menstrual period, different from the features of normal 
menstrual blood is called “Asrigdara” (4). 
In women it is a significant healthcare problem in 
the developed world (5) due to the increased stress. 
Between 25 - 58% of women participating in the WHO 
study reported having excessive bleeding per vaginum 
in the past three months (6, 7). One in 20 women aged 
30-40 consults their general practitioner every year 
complaining of heavy uterine bleeding (8). This 
potentially puts them under distressing condition in their 
social work place. 
The Nidanas are responsible for Asrigdara as 
described by Charaka are mostly Pitta Vardhaka (9). 
Without the influence of Vata Dosha, Yoni never gets 
vitiated; so all Y oni Vyapads & Artava Vyapads are 
because of Vata Dosha (10). Acharya Charaka also 
explained it as a symptom of Pittavrita Apanavayu (11). 
Various treatments like hormonal therapy, anti-
prostaglandins & anti-fibrinolytic agents are available in 
modern health science. Many side effects have been 
observed because of the medication and hysterectomy 
lead to hormonal imbalance and psychological upset in 
young fertile women. So keeping this in mind we took 
Ayurvedic drug trial, which are non-hormonal and safe 
that could provide effective alternative for Asrigdara. 
We have selected ‘Shunthi-Lodhra Churna with 
Sharkara’ which has been mentioned in “Y oga 
Ratnakar”  due to its contents, cost effectiveness and 
disease healing properties (12). 
The combinatorial formulation selected for our 
treatment based on the following properties. Shunthi has 
property of Kaphavata Nashana and Shula Prashamana 
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(13), Lodhra has Rakta Sthambhana and Garbhasaya 
Shothahara properties (14) and Sharkara for its Vata, 
Pitta, and Rakta Doshahara properties (15). So here we 
attempted to evaluate the efficacy of Shunthi-Lodhra 
Churna with Sharkara in the management of Asrigdara 
w.s.r. DUB. 
 
Objectives of the study 
 To evaluate the effect of Shunthi Churna and Lodhra 
Churna with Sharkara in the patients suffering from 
Asrigdara, on various scientific parameters. 
 
Materials and Methods 
Patients attending to the O.P.D of Prasuti Tantra 
& Stree Roga department, Uttarakhand Ayurved 
University, Rishikul Campus, Haridwar, were randomly 
selected based on the following inclusion and exclusion 
criteria’s. 
 
Inclusion criteria 
1. Patients aged between 18-45 years, with complaints 
of excessive bleeding per vagina during 
menstruation either in amount or in duration or both 
or during inter-menstrual period for 3 consecutive 
menstrual cycles. 
2. Patients who are using neither oral contraceptive 
pills nor IUCD for contraception or hormonal 
treatment. 
 
Exclusion criteria 
1. Patient suffering from DUB complicated by non-
responding anemia and confirmed for surgical 
interventions. 
2. All patients expected to have any organic 
involvement or those who cannot be labeled as 
DUB. 
3. Patients considered having extra genital factors for 
the uterine bleeding like thyroid dysfunction, liver 
dysfunction, coagulation disorders etc. 
4. Patients giving history of recent delivery or 
abortion. 
5. Patient having infections such as candidiasis, 
trichomonaliasis or any other form of vulvo-
vaginitis and pelvic congestion.  
6. Patients having systemic illness like TB, diabetes, 
and hypertension etc.  
 
Study design: Open level clinical tr ial 
 
Table-1: Posology 
 
Type of Study Single Group, open trial 
Period of Study 90 days 
Drugs used Shunti  and Lodhra Churna   
Dosage 
Shunthi Churna  (2 gms) + 
Lodhra  Churna (3gms)  3 
times a day after food  
 
Method of collection of data 
30 patients fulfilling the inclusive criteria were 
selected. Detailed history of patients was taken on pre-
designed specific proforma. History of present 
complaints with duration, associated symptoms, history 
of past illness (medical, surgical and drug history), 
personal history, menstrual history, obstetric history, 
contraceptive history were recorded. Other important 
points like marital status, socio-economic statuses were 
also noted. 
 
Investigations advised 
Blood Examination:  
Hb%, Total leucocyte count (TLC), Differential 
leucocytes count (DC), Erythrocyte sedimentation rate 
(ESR), Platelet count, Bleeding time (BT) and Clotting 
time (CT). 
Urine Examination:  
1- For routine and microscopic examination and  
2- For culture and sensitivity test. 
Stool Examination: routine and microscopic 
examination. 
Ultrasonography:  
For condition of uterus and adnexae, any pelvic 
pathology and thickness of endometrium (ET). 
 
Assessment criteria  
Scoring of the symptoms was done before, during 
and after the study, purely on the basis of patient’s 
explanations. 
 
A. Subjective Parameters 
Table-2: Showing the gradation of cardinal 
symptoms in the study 
 
 
Sahapana Sharkara (5gms) 
Route  Oral   
Anupana (mode of 
drug intake) 
With  cold water 
Observation During 
treatment 
At an interval  of 45 days till 
the completion of trial  (90 
days) 
Follow Up Time After 
treatment 
2 consecutive menstrual 
cycles after the 90 days of 
treatment period 
Symptoms / Criteria Score 
Amount of bleeding per menstrual cycle   
Complete soakage of< 3 pads in 24 hours 
(Average) 
0 
Complete soakage of 3-4pads in 24 hours 
(Moderately excessive) 
1 
Complete soakage of 5-7 pads in 24 hours 
(Excessive) 
2 
Complete soakage of or more than 7 pads 
in 24 hours (Very Excessive) 
3 
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Table-3: Showing the gradation of associated 
symptoms in the study 
 
 
 
Symptoms / Criteria Score 
Amount of bleeding per menstrual cycle   
Complete soakage of< 3 pads in 24 hours 
(Average) 
0 
Complete soakage of 3-4pads in 24 hours 
(Moderately excessive) 
1 
Complete soakage of 5-7 pads in 24 hours 
(Excessive) 
2 
Complete soakage of or more than 7 pads 
in 24 hours (Very Excessive) 
3 
Duration of menstrual bleeding   
Bleeding for <5days (Normal) 0 
 6-7 days (moderately prolonged) 1 
8-9 days (prolonged) 2 
> 9 days (very much prolonged) 3 
Inter-menstrual period   
25-30 days (normal) 0 
20-24 days (short) 1 
15-19 days (very short) 2 
< 15 days (highly abnormal) 3 
Pain during menstruation   
No pain 0 
Mild pain. Women complain of pain but 
do not require any medication for relief 
1 
Moderate pain. Women complain of pain 
and take one or two doses of drugs for 
relief. The pain doesn’t affect her routine 
life 
2 
Severe pain, women complain of pain and 
take 3-4 doses of drugs for relief. The 
pain influences the general routine 
activities 
3 
Passage of clots   
No history of passing clots with menstrual 
bleeding 
0 
Occasionally bleeding with clots (1-2 
cycles only) 
1 
Frequent clots but bleeding without clots 
are also observed in few cycles in 
between 
2 
Bleeding with clots in each menstrual 
cycle 
3 
Associated Symptoms Score 
Angamarda 
Absent 0 
Present 1 
Daurbalya 
Absent 0 
Present 1 
Bhrama 
Absent 0 
Present 1 
 
 
B. Objective Parameter: Hb% 
 
Table-4: Showing the gradation of Hb% in the study 
 
The values of both subjective and objective 
parameters were noted before, during (after 45 days) 
and after the treatment to assess the effect of therapy. 
 
Criteria to assess the results: 
 Cured: 100%  relief 
 Marked improved:  More than 76% relief 
 Moderate improvement: 51%  to 75%  relief 
 Mild improvement: 25%  to 50%  relief 
 No improvement: <25%  relief 
 
Table-5: Demographic observation of total 
registered patients (n=30)
 
 
Results of Clinical Trial  
The effect of the treatment was analyzed 
statistically by calculating the mean, standard deviation, 
standard error, t and p-values by using Paired t-test 
between the observations before treatment verses after 
45 days of treatment and between the observations 
before treatment verses after the completion of 
treatment. 
Aruchi 
Absent 0 
Present 1 
Daha 
Absent 0 
Present 1 
Trusha 
Absent 0 
Present 1 
Hb % Gradation 
Normal (> 11 gm %) 0 
Mild (9-11 gm %) 1 
Moderate (7-9 gm %) 2 
Severe (< 7 gm %) 3 
Observations Pre-
dominance 
No. of 
patients 
% 
Age 29-37yrs 12 40 
Habitat Rural 15 50 
Marital Status Married 26 86.6 
Educational 
status 
High School 9 30 
Socio-economic 
status 
Middle 
Class 
20 66.6 
Occupations House Wife 19 63.3 
Dietary habit Katu Rasa 8 26.6 
Psychological 
Status 
Agitated 15 50 
Parity Multi 21 70 
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Table-6: Showing changes in cardinal symptoms before and during the treatment (n=30) 
 
 
Table-7: Showing changes in cardinal symptoms before and after the treatment 
 
 
Table-8: Showing changes in associated symptoms before and during the treatment 
 
 
Table-9: Showing changes in associated symptoms before and after the treatment 
 
 
Table-10: Showing changes in Hb% before and during the treatment
 
 
Table-11: Showing changes in Hb% before and after the treatment 
 
Chief complaints Mean Diff. (BT-
DT) 
% 
Change 
S.D S.E ‘t’ p-value 
BT DT 
Amount of bleeding 1.76 1.16 0.6 33.9 0.63 0.08 6.7 <0.001 
Duration of bleeding 1.93 1.23 0.7 36.2 0.55 0.08 8.36 <0.001 
Inter-menstrual 
bleeding 
1.93 1.3 0.63 32.7 0.64 0.08 7.19 <0.001 
Clots 1.7 1.2 0.5 29.4 0.65 0.09 5.47 <0.001 
Pain during 
Menstruation 
1.63 0.96 0.66 40.8 0.65 0.09 6.79 <0.001 
Chief complaints Mean Diff. (BT- 
AT) 
% Change S.D S.E ‘t’ p-value 
BT AT 
Amount of bleeding 1.76 0.73 1.03 58.5 0.72 0.137 7.52 <0.001 
Duration of bleeding 1.93 0.8 1.13 58.6 0.47 0.11 10.5 <0.001 
Inter-menstrual 
bleeding 
1.93 0.96 0.97 50 0.65 0.09 9.67 <0.001 
Clots 1.7 0.9 0.8 47 0.65 0.1 7.29 <0.001 
Pain during 
Menstruation 
1.63 0.66 0.96 59.1 0.83 0.12 8.04 <0.001 
Associated 
symptoms 
Mean Diff. 
(BT- DT) 
% Change S.D S.E ‘t’ p-value 
BT DT 
Angamarda 0.9 0.5 0.4 40.7 0.48 0.08 4.47 < 0.001 
Daurbalya 0.83 0.63 0.2 24 0.4 0.07 2.73 < 0.05 
Bhrama 0.73 0.5 0.23 31.8 0.42 0.07 3.02 < 0.05 
Aruchi 0.73 0.3 0.43 50 0.4 0.09 4.78 < 0.001 
Daha 0.7 0.53 0.16 23.8 0.3 0.06 2.44 < 0.05 
Trisha 0.7 0.53 0.16 23.8 0.3 0.06 2.44 < 0.05 
Associated 
symptoms 
Mean Diff. (BT- AT) % Change S.D S.E ‘t’ p-value 
BT AT 
Angamarda 0.9 0.36 0.53 59.2 0.4 0.09 5.8 <0.001 
Daurbalya 0.83 0.43 0.4 48 0.5 0.1 3.95 <0.001 
Bhrama 0.73 0.36 0.36 50 0.5 0.09 3.66 <0.001 
Aruchi 0.73 0.16 0.56 77 0.4 0.09 6.25 <0.001 
Daha 0.7 0.43 0.26 38 0.4 0.08 3.29 <0.05 
Trisha 0.7 0.46 0.23 33.3 0.4 0.07 3.01 <0.05 
  Mean Diff. % Change S.D S.E ‘t’ p-value 
BT DT 
Hb % 9.8 10.0 0.2 2.3 0.5 0.74 2.49 <0.05 
  Mean Diff. % Change S.D S.E ‘t’ p-value 
BT AT 
Hb % 9.8 10.5 0.75 7.68 0.6 0.11 6.76 <0.001 
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Overall Effect of Treatment: 
Table-12: Distribution of patients based on 
Overall effect of treatment  
 
The overall effect of treatment on the 
different symptoms stands out as we observed 60% of 
patients studied have improved moderately, followed by 
mild improvement in 36.7% of patients. We didn’t 
observe any patients under no improvement category. 
We have observed only one patient (3.3%) within 
marked improvement group but none in cured category. 
 
Results and Discussion 
Effect of therapy on Subjective parameters of 
Asrigdara: 
Cardinal Symptoms  
While analyzing the changes before, during (after 
45 days) and at the end of the treatment period (90 days 
post-treatment) we observed that the amount of blood 
loss was reduced to 34% during and to 59% after the 
completion of treatment. Highly significant reduction 
was observed in duration of blood loss (36% during and 
59% after) at the end of the treatment period. We 
observed an improvement by 33% during and 50% at 
the end in the inter-menstrual period. While analyzing 
the changes we observed reduction in passage of clots 
by 29% during and by 47% after the treatment. We also 
observed pain relief during menstruation by 41% during 
and 59% at the end of the treatment period in our treated 
patient groups (Table-2, 6-7). 
 
Associated symptoms 
In Angamarda, 41% relief was found during and 
59% after the treatment. In Daurbalya, 24% relief was 
observed during and 48% after the treatment. In Aruchi, 
50% relief was observed during and 77% after the 
treatment. In Bhrama, 32% relief was found during and 
50% after the treatment. In Daha, 24% relief was found 
during and 38% after the treatment. In Trishna, 24% 
relief was found during and 33% at the end of the 
Criteria to 
assess the 
results 
No. of 
patients 
(n=30) 
Percentage 
(%) 
No improvement 
(< 25%) 
0 0 
Mild 
improvement  
(25-50 %) 
11 36.7 
Moderate 
improvement  
(51-75 %) 
18 60 
Marked 
improvement  
(76-99 %) 
1 3.3 
Cured  
(100 %) 
0 0 
treatment in our patients. The results were significant in 
most of the observations (Table-3, 8-9). 
The observed values of TLC, DLC, ESR, BT, and 
CT, Platelet count, Urine and Stool examinations before 
treatment were within normal limits. Asrigdara is not an 
infective disease. So TLC, DLC, ESR, urine and stool 
examinations might have been normal. Excessive 
bleeding due to any coagulation disorders were kept in 
exclusion criteria, so only the cases having normal 
bleeding time, clotting time and platelet count were 
included in the study. 
 
Effect of therapy on objective parameter of 
Asrigdara 
Before, during and after the treatment period 
Hb% was analyzed, and we observed highly significant 
improvement in the Hb% after the end of the 
investigation period of treatment (Table-4, 10-11). 
 
Overall effect of therapy: 
The total effect of treatment in our treated 
patients, on the basis of criteria of assessment adopted, 
has shown that 60% of patients studied have improved 
moderately, followed by mild improvement in 36.7% of 
patients.  We didn’t observe any patients under no 
improvement category (Table-12). We have observed 
only one patient (3.3%) within marked improvement 
category but none in cured category. 
 
Probable mode of action of the drugs in treating 
Asrigdara: 
Shunthi:  
 Acharya Charaka has explained Asrigdara is a 
symptom of Pittavrita Apanavayu and Acharya Sushruta 
mentioned it under Pitta samyukta Apana (16), Katu 
Rasa, Ushna Virya, Dipaniya, Vatanulomaka, Vibandha 
Nashaka (17, 18), properties of Shunthi helps to 
normalize the movement of Apana Vayu that has get 
obstructed by Pitta in the Artavavaha Srotasa. Due to 
Dipaniya and Pachaniya properties (19) it regularizes 
the function of Y akrita, hence metabolism of oestrogen 
becomes normal. So we hypothesized to see the positive 
effect in regulating the menstrual cycle and also the 
subsidation of symptoms like Ajirna, Aruchi (20) due to 
Amadosha Pachana. 
Previous clinical research have shown that ginger, 
one of the forms of Shunthi can reduce symptoms of 
dysmenorrhea in some women when taken in a specific 
extract composition (Zintoma, Goldaru) (21). The 
extract of ginger blocks the formation of inflammatory 
compounds such as thromboxane, leukotrine and 
prostaglandins, thus acts as an anti-inflammatory 
substance (22). Hence,we believe this could have 
positive regulatory effect on dysmenorrhea. Due to anti-
inflammatory effect it is expected to pacify the pelvic 
congestion (high vascularity), thus the amount of blood 
loss gets reduced.   
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Lodhra:  
In the pathogenesis of Asrigdara, Chala Guna of 
Vata Dosha, Sara and Drava Guna of Pitta Dosha (23) 
increases the amount of blood. Hence this drug might 
affect the Sara and Drava Guna of Pitta Dosha with the 
help of Ruksha, Laghu Guna and Kashaya Rasa (24, 
25). So this could be the reason in reducing the amount 
of bleeding. Laghu, Ruksha Guna having Kapha-Pitta 
Shamaka (26) and Shoshana property (27) helps in 
Sroto Shodhana. Production of oestrogen is also 
increased by the use of fatty products in diet. Fatty 
materials have shown to increase the cholesterol in the 
blood circulation. Cholesterol is the precursor of all 
steroidal hormones; especially in female it is 
responsible for more production of oestrogen (28). 
Kapha Shamaka and Lekhaniya Karma are probably 
carried out by Laghu and Ruksha Guna (29) of Lodhra, 
therefore it decreases the production of oestrogen 
leading to reduced hyperplasia of endometrium. 
Biochemically Lodhra contains 3-
monoglucofuronoside of 7-methyl leucopelagonidin, 
which makes it glycosidic in nature, which also exerts 
vaso-constrictive action and reduces the permeability of 
cell membrane. It has also shown anti-fibrinolytic 
activity. Ethanolic extract from bark also acts as an 
analgesic, anti-inflammatory and antioxidant (30). 
These properties are considered helpful in reducing the 
amount of bleeding. 
 Trishna results from the Rakta Kshaya i.e 
the loss of fluids from the body. Anaemic condition 
results in neuritis, which expresses itself as Daha. Due 
to Grahi Guna (vaso-constrictive action) of   Lodhra is 
expected to have positive effect in curing Trishna and 
Daha by reducing the blood loss (31). It also pacifies 
Daha and Trisha due to its Sheeta Virya (32). 
In a published in–vivo study, Lodhra has been 
shown to be useful and have an effect on regularizing 
menstrual cycle and also in ovulation (33). In another 
published report the effect of ethanolic extract of 
Symlocos recemosa bark powder in treating female 
reproductive dysfunction in a rat experiment showed 
significant decrease in the duration of pro-estrous phase 
and a significant increase in the duration of estrous, 
metestrous, diestrous phases (34). 
Another report to test the hepato-protective effect 
of Symplocos racemosa Roxb, showed significantly 
reduction on the levels of hepatic enzymes and total 
bilirubin (35). In Asrigdara, Yakrita and Pliha get 
vitiated. So the hepato-protective activity (36) of 
Symlocos recemosa regulates the conjugation and 
metabolism of female hormones, which results in 
maintaining a normal menstrual cycle. Bhrama occurs 
due to blood loss, the haemostatic effect (Raktasrava 
nashaka of Lodhra might have effect in controlling 
Bhrama). 
The main component of Lodhra is large amount 
of loturine alkaloid and it also contains à-spinosteral. 
Spinosteral had been shown to have anti-inflammatory 
activity on isolated guinea pig ileum. It is suggested that 
Lodhra might have influenced the endometrial 
prostaglandin apparatus, thereby acting effectively in 
the control of dysfunctional uterine bleeding (37). 
 
Sharkara 
Due to Madhura Rasa, Sheeta Virya, Madhura 
Vipak (38, 39) Sharkara pacifies Pitta and Rakta, which 
is the main physiological factor in producing Asrigdara. 
Sharkara is very sweet and increases the taste, 
mitigates Vata, Pitta, Rakta, burning sensation, fainting, 
vomiting and fever (40). Madhura Rasa increases better 
palatability. Due to Madhura Rasa it acts as Balya, 
Bringhaniya, so the symptoms Daurbalya might have 
improved (41). It pacifies ‘Raktapitta (42), Acharya 
Sushruta also mentioned Asrigdara to be treated just 
like treatment of Raktapitta. Because of its Sheeta Virya 
(43) property, it pacifies Daha, Trisha, and Raja. So it 
might have effect to normalize the abnormal menstrual 
cycle. Bhrama, Murchha etc. occur due to cerebral 
hypoxia resulting from the reduced oxygen carrying 
capacity of blood. Due to reduction in the amount of 
blood loss, it could have helped in curing Bhrama. 
 
Conclusion 
The main principle of the management of 
Asrigdar is deepana-pachana, Agni vardhana, rakta 
sthapana etc (44). Present research work was on the 
basis of observations and results of trial drug, 
pharmacological virtue and chemical constituents. The 
drugs Shunthi Churna and Lodhra Churna with 
Sahapana Sharkara possess Rakta Stambhaka  
Vatapitta Shamaka & Vatanulomaka properties. Our 
tested drug combination has shown to be effective in 
excessive and prolonged bleeding by reducing both 
amount and duration of blood loss, normalizing inter-
menstrual period and also for relief in pain and 
improvement in consistency of blood. The drug 
combination also found to reduce the associated 
symptoms like Angamarda, Daurbalya, Aruchi, Daha, 
Bhrama and Trisha. 
From the above findings and observations, we 
can conclude that the drug formulation Shunthi Churna 
and Lodhra Churna with Sharkara, proved to be 
effective in treating most of the symptoms of Asrigdara. 
 
References 
1. Dutta DC. Text book of Gynaecology. Edited by 
Hiralal Konar, 5 ed. Calcutta; New central book 
agency; 2009. 183p. 
2. Dutta DC. Text book of Gynaecology. Edited by 
Hiralal Konar, 5 ed. Calcutta; New central book 
agency; 2009. 79p. 
3. Agnivesha, Charaka, Dridhabala. Charaka Samhita, 
Chikitsha Sthana, Yoni Vyapad Chikitsha, 30/209. 
Edited by Pt. Rajeswaradatta Shastry and Pt. 
Published online in http://ijam. co. in 
45 
Swatirekha Mohapatra et.al., Efficacy of Shunthi-Lodhra Churna in the Management of Asrigdara (DUB) 
ISSN: 0976-5921 
Yadunandana Upadhyaya, Varanasi; Chaukhambha 
Bharati Academy; 2011. 868p. 
4. Maharshi Sushruta. Sushruta Samhita, Sharira 
Sthana, Shukrashonita Shuddhi Sharira, 2/20. 
Edited by Kaviraja Ambikadutta Shastri, Varanasi; 
Chaukhambha Sanskrit Sansthan; 2009. 15p. 
5. Robert W Shaw, W.P Soutter, Stuart L Stanton. 
Gynaecology. 3 ed. Churchill Livingstone; 2003. 
464-465p. 
6. Omran AR, Standley CC, Family Formation 
Patterns and Health. An International Collaborative 
Study in India, Iran, Lebanon, Philippines and 
Turkey. Geneva: World Health Organization. 1976; 
335 – 372  
7. Omran AR, Standley CC, Family Formation 
Patterns and Health Further Studies. An 
International Collaborative Study in Columbia, 
Egypt, Pakistan, and the Syrian Arab Republic. 
Geneva: World Health Organization. 1981; 271 – 
302 
8. Telner DE, Jakubovicz D, Approach to diagnosis 
and management of abnormal uterine bleeding. Can 
Fam Physician. Jan, 2007; (53); 58-64 
9. Agnivesha, Charaka, Dridhabala. Charaka Samhita, 
Chikitsha Sthana, Yoni Vyapad Chikitsha, 30/209. 
Varanasi; Chaukhambha Bharati Academy; 2011. 
868p. 
10. Agnivesha, Charaka, Dridhabala. Charaka Samhita, 
Chikitsha Sthana, Yoni Vyapad Chikitsha, 30/115. 
Varanasi; Chaukhambha Bharati Academy; 
2011.858p. 
11. Agnivesha, Charaka, Dridhabala. Charaka Samhita, 
Chikitsha Sthana, Vata Vyadhi Chikitsha, 28/229. 
Varanasi; Chaukhambha Bharati Academy; 2011. 
815p. 
12. Lakshmipati Vaidya Shastri. Yoga Ratnakara, 
Uttarardha, Streerogadhikar, Pradara Chikitsha, 
Shloka no-18. Edited by Bhisagratna Brahmasankar 
Shastri, Varanasi; Chaukhambha Prakashan; 2013. 
396-401p. 
13. Shree Madan Pal. Madanpal Nighantu, Shunthyadi 
Varga, Shloka no.3-4. Edited by Gyanendra Pandey. 
1 ed. Varanasi; Chaukhambha Orientalia; 2012. 
72p. 
14.  Priya Vrat Sharma. Dravayaguna Vijnana, 
Triptighna Varga, Vol.2. Varanasi; Chaukhambha 
Bharati Academy; 2006. 617p. 
15. Narahari Pandit. Raja Nighantu, Paniyadi Varga, 
Shloka no.104. Edited by Indradeva Tripathy. 
Varanasi; Chaukhamba Krishnadas Academy; 2010. 
493p. 
16. Maharshi Sushruta. Sushruta Samhita, Sharira 
Sthana, Nidana Sthana, Vata Vyadhi Nidanam, 
1/37. Edited by Kaviraja Ambikadutta Shastri, 
Varanasi; Chaukhambha Sanskrit Sansthan; 2009.  
299p.   
17. Acharya Sodhala. Sodhala Nighantuh, Haritakyadi 
Varga.  Edited by R.R. Dwivedi. 1ed. Varanasi; 
Choukhambha Krishnadas Academy; 2009. 83p. 
18. Vagbhata. Ashtanga Hridaya, Sutra Sthana, 
Annaswarupavijnaniyadhyaya, 6/163, edited by 
Brahmanand Tripathy. Delhi; Chaukhamba Sanskrit 
Pratisthan; 2009. 120p. 
19. Kaiyadev. Kaiyadev Nighantu, Oushadhi Varga, 
Shloka no.1151-1152. Edited by Priya Vrat Sharma. 
Varanasi; Chaukhambha Orientalia; 2009. 213p. 
20. Dhanvantari Nighantu. Shatapushpadi Varga, Shloka 
no.83. Edited by Priya Vrat Sharma. Varanasi; 
Chaukhambha Orientalia; 85p. 
21. Natural medicines comprehensive database; www. 
Naturaldatabase.Com. 
22. Gouda PR, Naidu ML. The effect of Ayurvedic 
drugs when used as disease-modifying Anti-
rheumatic drugs in Amavata. Int. J. Res. Ayurveda 
Pharm. 2012; 3(1); 27-31 
23. Agnivesh, Charaka, Dridhabala. Charaka Samhita, 
Sutra Sthana, Dirghanjibitiya Adhyaya, 1/59-60. 
Edited by Brahmanand Tripathy. Varanasi; 
Chaukhambha Surbharati Prakashan; 2010. 32p. 
24. Srimad Bhav Mishra. Bhavprakash Nighantu, 
Haritakyadi Varga, Shloka no.215. Edited by G.S. 
Pandey. Varanasi; Chaukhambha Bharati Academy; 
2013. 124p. 
25. Dhanvantari Nighantu. Chandanadi Varga, Shloka 
no.156. Edited by Priya Vrat Sharma. Varanasi; 
Chaukhambha Orientalia; 119p. 
26. Bapalal G. Adarsha Nighantu, Vol I.Varanasi; 
Chaukhambha Bharati; Reprint: 2007.  
27. Priya Vrat Sharma. Priya Nighantu, Haritakyadi 
Varga, Shloka no.143. Varanasi; Chaukhambha 
Surbharati Prakashan;    2004. 33p.  
28. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5 
Ed. New York; W H Freeman; 2002, 26(4).1.  
29. Agnivesh, Charaka, Dridhabala. Charaka Samhita, 
Sutra Sthana, Langhanbrihmniya Adhyaya, 22/12. 
Edited by Brahmanand Tripathy. Varanasi; 
Chaukhambha Surbharati Prakashan; 2010. 413p. 
30. Bhusnar H U, Nagore D H, Nipanikar S U. 
Phytopharmacological profile of Symplocos 
racemosa. Pharmacologia. 2014; 5(2); 76-83. 
31. Kaiyadev. Kaiyadev Nighantu, Oushadhi Varga, 
Shloka no.1126. Edited by Priya Vrat Sharma. 
Varanasi; Chaukhambha Orientalia; 2009. 278p. 
32. Narahari Pandit. Raja Nighantu, Pippalyadi Varga, 
Shloka no.212. Edited by Indradeva Tripathy. 
Varanasi; Chaukhamba Krishnadas Academy; 2010. 
177p. 
33. Bhutani K Kr, Jadhav A N, Kalia V. Effect of 
Symplocos racemosa Roxb. on gonadotropin release 
in immature female rats and ovarian histology. 
Journal of Ethnopharmacology. 2004; 94; 197-200. 
34. Gupta Santosh Kumar, Gupta Amit, Kumar 
Sokindar, Pandey prabhakar. Adaptogenic activity of 
Symplocos racemosa bark on female reproductive 
Published online in http://ijam. co. in 
46 
International Journal of Ayurvedic Medicine, 2019, 10(1), 39-46 
ISSN: 0976-5921 
dysfunction in rats. International conference on 
global trends in pure and applied chemical sciences. 
Abstract published in 3rd-4th march 2012, Udaipur, 
Rajasthan, India. 
35. Venkidesh R, Pal D, Ashok Kumar C.K, 
Saravanakumar A and Mandal SC. 
Hepatoprotective Activity of Symplocos racemosa 
Roxb. Bark Extract in Carbon tetrachloride induced 
Liver Damage in Rats. Int. J of Innovative 
Phamaceutical Research. 2011; 2(3); 147-150. 
36. Wakchaure, D Jain D, Singhai AK and Somani R. 
Hepatoprotective activity of Symlocosrecemosa 
bark on carbon tetrachloride- induced hepatic 
damage in rats. J Ayurveda Integr Med. 2011; 2(3); 
137-143. 
37. Devi K P. Clinical evaluation of Pusyanuga 
Choorna and Lodhrasava in Raktapradara (DUB). 
Indian Journal of Traditional knowledge. 2007; 6
(3);429- 31 
38. Priya Vrat Sharma. Priya Nighantu, Drava Varga, 
Shloka no.51. Varanasi; Chaukhambha Surbharati 
Prakashan;    2004. 236p. 
39. Shree Shaligram, Shaligram Nighantu, Ikshu Varga, 
Khemraja Srikrishnadas Prakashan, Mumbai-4. 
2011. 806p.  
40. Srimad Bhav Mishra. Bhavprakash Nighantu, 
IkshuVarga, Shloka no.30. Edited by G.S. Pandey. 
Varanasi; Chaukhambha Bharati Academy; 2013. 
780p. 
41. Agnivesh, Charaka, Dridhabala. Charaka Samhita, 
Atreyabhadrakapya Adhyaya, 26/42. Edited by 
Brahmanand Tripathy. Varanasi; Chaukhambha 
Surbharati Prakashan; 2010. 481p. 
42. Maharshi Sushruta. Sushruta Samhita, Sharira 
Sthana, Dravadravyavidhimadhyaya, 45/168. Edited 
by Kaviraja Ambikadutta Shastri, Varanasi; 
Chaukhambha Sanskrit Sansthan; 2009.  236p. 
43. Dhanvantari Nighantu. Shatapushpadi Varga, 
Shloka no.102. Edited by Priya Vrat Sharma. 
Varanasi; Chaukhambha Orientalia; 89p. 
44. Pal M, Sharma P, Jain C M, Sharma S. Clinical 
study to evaluate the effect of Bolbaddha Rasa in 
Asrigdar. Int. J. Res. Ayurveda  Pharm. Jan-Feb, 
2016; 7(1); 53-56. 
***** 
